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Abstract
Background: Infection with human papillomavirus (HPV) is associated with uterine cervical intraepithelial neoplasia
(CIN) and invasive cancers (ICC). Approximately 80% of ICC cases are diagnosed in under-developed countries.
Vaccine development relies on knowledge of HPV genotypes characteristic of LSIL, HSIL and cancer; however, these
genotypes remain poorly characterized in many African countries. To contribute to the characterization of HPV
genotypes in Northeastern Tanzania, we recruited 215 women from the Reproductive Health Clinic at Kilimanjaro
Christian Medical Centre. Cervical scrapes and biopsies were obtained for cytology and HPV DNA detection.
Results: 79 out of 215 (36.7%) enrolled participants tested positive for HPV DNA, with a large proportion being
multiple infections (74%). The prevalence of HPV infection increased with lesion grade (14% in controls, 67% in
CIN1 cases and 88% in CIN2-3). Among ICC cases, 89% had detectable HPV. Overall, 31 HPV genotypes were
detected; the three most common HPV genotypes among ICC were HPV16, 35 and 45. In addition to these
genotypes, co-infection with HPV18, 31, 33, 52, 58, 68 and 82 was found in 91% of ICC. Among women with CIN2-
3, HPV53, 58 and 84/83 were the most common. HPV35, 45, 53/58/59 were the most common among CIN1 cases.
Conclusions: In women with no evidence of cytological abnormalities, the most prevalent genotypes were HPV58
with HPV16, 35, 52, 66 and 73 occurring equally. Although numerical constraints limit inference, findings that 91%
of ICC harbor only a small number of HPV genotypes suggests that prevention efforts including vaccine
development or adjuvant screening should focus on these genotypes.
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Background
Globally, cervical cancer remains the third most com-
mon cancer, representing 8.8% of all cancers in women
[1]. Infection with human papillomavirus (HPV) is asso-
ciated with low-grade (LSIL) and high-grade (HSIL)
intraepithelial precursor lesions of the uterine cervix as
well as invasive cervical cancer (ICC) [2]. More than
200 HPV genotypes, subtypes and variants have been
reported [3], of which approximately 14 genotypes are
classified as oncogenic [4,5]. HR-HPV DNA is detected
in almost all ICC cases [6].
In developed and in many less-developed countries,
assessing the effectiveness of prophylactic vaccines
against HR-HPV16 and 18, and further vaccine develop-
ment will depend on knowledge of the distribution of
these HPV genotypes in different regions [7-10]. HPV
types 16 and 18 are consistently the two most common
types in invasive cancer, globally. One study suggested
that vaccination against HPV16 and 18 could prevent
almost 70-80% of ICC worldwide-[11]. It has been sug-
gested that vaccine efficacy could be increased to 95%
for CIN2-3 and 92% for cancer by including an addi-
tional 12 HPV genotypes detected in an Icelandic
women population [7]. However, data collected from
different countries have shown fluctuations in the
* Correspondence: cathrine.hoyo@duke.edu
1Department of Community and Family Medicine, and Program of Cancer
Detection, Prevention and Control, Duke University School of Medicine,
Durham, NC, USA
Full list of author information is available at the end of the article
Vidal et al. Infectious Agents and Cancer 2011, 6:20
http://www.infectagentscancer.com/content/6/1/20
© 2011 Vidal et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.distribution of the third and even less common onco-
genic HPV types between regions [9,12].
Given the suboptimal sensitivity and specificity of
cytology-based screening, and the low screening cover-
age in most African countries, immunization against the
most prevalent HR-HPV genotypes affecting each region
may represent the most effective means to long-term
ICC prevention [13]. To date, few studies describing sin-
gle and multiple HPV infections according to CIN
grades have been conducted in African populations
where a wide range of HPV genotypes prevail [14-16].
Moreover, many of these studies have not described
HPV infection in ICC cases [17,18]. Herein we report
on the distribution of HPV genotypes in Northeastern
Tanzania, with the aim of identifying the most frequent
HPV genotypes associated with different CIN grades
and ICC in this population.
Methods
Study participants
Procedures for this study were approved by Research
Ethics Boards at KCMC and Duke University. Between
November 2008 and March 2009, eligible study partici-
pants were identified from the appointment books of the
Reproductive Health Clinic (RHC) at Kilimanjaro Chris-
tian Medical Centre (KCMC), a Cervical Cancer preven-
tion clinic funded by the World Health Organization
(http://www.afro.who.int/en/tanzania/who-country-office-
tanzania.html). KCMC is a tertiary care facility that serves
a catchment area of ~10 million individuals. Eligible parti-
cipants were 18 years or older and had no history of an
abnormal Pap test. ICC patients comprised new cases to
the KCMC who were also 18 years or older and were
referred for colposcopic directed evaluations. A trained
nurse interviewer enrolled a total of 249 women; all but 2
approached agreed to participate (99% response rate). Of
these, 12 patients were excluded due to missing or inade-
quate Pap smear, refusal of serostatus HIV-1 antibody test,
and diagnosis of an unrelated co-morbid condition. The
final dataset of participants, n = 215 (86%), were those
with questionnaire, CIN status, and HPV genotype data.
Data collection
Questionnaires
A trained nurse-interviewer obtained informed consent
from all participants, and administered a standardized
40-minute questionnaire, in person. The questionnaire
collected information on socio-demographic characteris-
tics (e.g., age, marital status), type of marriage (polygamy
vs. monogamy), tribe, educational attainment, cigarette
smoking, alcohol intake, reproductive history (e.g.,
menarche, parity and gravidity), sexual history (e.g., life-
time number of sexual partners, age at first intercourse),
and medication and supplement use.
Specimens
Two cervical scrapes were obtained from each partici-
pant using Ayres spatula and Cytobrush. One specimen
was smeared on a glass slide for cytological evaluation
for patient care. A second specimen was collected using
a Cytobrush and rinsed into Preserv- Cyt™ media
(Hologic, Inc, Malborough, MA). Following specimen
collection, routine cervical screening by Visual Inspec-
tion with Acetic acid (VIA) was performed. Biopsies of
lesions were obtained during colposcopy when indicated.
Patients with positive findings by VIA or direct exami-
nation were triaged and treated accordingly. The
remaining patients were given return appointments to
follow up on results within two weeks, and were treated
accordingly.
Ascertainment of CIN and Carcinoma
Papanicolaou smears and biopsy specimens were pro-
cessed and read by the staff pathologist at KCMC- using
standard conventions according to ASCCP guidelines as
appropriate (http://www.asccp.org/). Once a month,
medical charts were reviewed by BV for HIV-1 test and
cyto-pathological results, to classify cases using the
Bethesda classification system [19]. Based on pathology
and medical records findings, results were then coded as
“no evidence of cytological abnormality”, “mild dyspla-
sia” including LSIL and CIN1, “moderate dysplasia”
including HSIL and CIN2-3, or “cancer” which included
squamous cell carcinoma and two adeno-squamous car-
cinomas of the uterine cervix. None of the specimens
were read as “atypical cells of uncertain significance
(ASCUS)”. These results were available as part of their
clinic records, and pathologists entered them into the
database. These clinical results were then compiled and
transferred securely to Duke University.
HPV genotyping
ThinPrep
® specimens and homogenized aliquoted biop-
sies collected during the same visit were shipped to the
University of Hawaii Cancer Center. Following DNA
extraction, PGMY09/PGMY11 primers [20] were used
in PCR to target a 450-bp region of the HPV L1 gen-
ome. Amplification of the human b-globin gene was
included as an internal control for sample sufficiency.
All specimens were suitable for viral DNA analysis.
HPV-positive specimens were subsequently genotyped
by using the HPV Linear Array
® (Roche Molecular Sys-
tems Inc., Branchburg, NJ, USA).
Ascertainment of HIV-1 infection status
Peripheral blood samples were centrifuged to separate
the plasma and buffy coat. Plasma samples were used to
test for HIV-1 infection using two rapid HIV tests
(Capillus HIV-1/HIV-2, Trinity Biotech PLC, Bray,
C o u n t r yW i c k l o w ,I r e l a n d ,a n dD e t e r m i n eH I V - 1 / 2 ,
Abbott Laboratories, Abbott Park, IL). Reactive speci-
mens were then tested using Western blot as is standard
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kit; Bio-Rad, Hercules, CA) [21].
Statistical analyses
For each disease endpoint (CIN1, CIN2-3, ICC and
women with no evidence of cervical abnormalities), we
computed the proportion of single and multiple HPV
infections, and grouped them according to potential
oncogenicity using WHO-recommended categories [22].
Group 1 comprises high-risk (HR) or the most potent
type HPV16, followed by HPV18, 31, 33, 35, 39, 45, 51,
52, 56, 58, and 59; group 2A includes HPV68; group 2B
includes HPV26, 53, 66, 67, 70, 73, and 82 with limited
evidence for human cervical cancer; and group 3
includes low-risk (LR) HPV types 6 and 11 [22]. We
estimated the average number of HPV infections per
woman by dividing the total number of HPV genotypes
in multiple infections by the number of women infected.
To estimate the attribution of each HPV genotype to
CIN or ICC beyond the known HR-HPV, we estimated
proportions in each case group with and without HR-
HPV genotypes. Statistical analyses were conducted
using SAS 9.2 (SAS Institute, Cary, NC).
Results
Cervical cytology and HPV testing was conducted
among 215 Northern Tanzanian women, 55% were
Chaga, 15% were Pare and 30% were from other tribes.
Although the median age of all cases was 45 years,
women with no evidence of cervical abnormalities or
controls (mean age 40.3 years, sd = 9.87), and CIN1
cases (mean age 35.7 years sd = 12.2) were younger
than women with CIN2-3 and ICC whose mean ages
were 44.7 years, (sd = 9.82) and 55.2 years, (sd = 12.3),
respectively. Controls and case groups did not vary sig-
nificantly by tribe, cigarette smoking and lifetime num-
ber of sexual partners, although controls were less
likely to be infected with any HPV. HIV-1 infection
was more frequently reported by CIN than ICC cases
or controls while OC use was more frequently
reported by CIN cases and controls than ICC cases
(Table 1).
Table 2 shows the total number of HPV-infected indi-
viduals and the distribution of HPV genotypes by cervi-
cal intraepithelial lesion or cervical cancer status. Of 215
participants, 79 (36.7%) were HPV-positive and of these,
20 (25%) had no evidence of cytological abnormality, 12
(15%) had CIN1, 14 (17%) had CIN2-3, and 33 (41%)
had cervical cancer. Among 134 HPV negative women,
only 4 (3%) had cancer, 6 (4.5%) had CIN1, and 2 (1.5%)
had CIN2-3. Overall, 31 distinct HPV genotypes were
detected, and their detection rates, including co-infec-
tion with more than one genotype are illustrated in
Table 2. The prevalence of HPV infection increased
with lesion grade: 14% in controls, 67% in CIN1 cases,
88% in CIN2/3 and 89% in ICC.
HPV genotypes in women with CIN1
HPV DNA was detected in 67% of CIN1, and 50% of
the HPV detected were of HR genotypes. On average,
there were approximately 3 HPV genotypes per CIN1
case (range 0-9). Sixty percent of women with CIN1
lesions had multiple infections. In order of prevalence,
the seven most frequent HR-HPV genotypes detected
among CIN1 cases were: 35, 45, 53, 58, 59, 16, and 51,
followed by low risk (LR) type HPV55. In two indivi-
duals the rare HPV62 type was detected (Table 2).
HPV genotypes in women with CIN2-3
HPV DNA was detected in 88% of CIN2-3; on average 4
HPV genotypes were detected per case (range, 0-9) as
also found for women with CIN1. High-risk HPV sub-
types were found either as single or multiple infections
in 57% of CIN2-3 cases. In contrast to 73% of ICC
which harbored the HPV16 genotype, only 3 (14%)
CIN2-3 cases, 2 (17%) CIN1 cases and four controls
(15%) had detectable HPV16 DNA. Multiple HPV infec-
tions were also common among CIN2-3 cases with 75%
showing HPV coinfections. Also as in CIN1, 50% of the
HPV genotypes detected were HR while the remainder
were LR or other types of unknown oncogenic potential.
HPV53, 58, 16, 18, 31, 33, and 35, were the seven most
frequent types detected among women with CIN2-3, in
order of decreasing frequency (Table 2). LR-HPV geno-
types were detected in CIN1 and CIN2-3 lesions only in
the context of multiple infections with HR genotypes.
HPV genotypes in women with ICC
HPV DNA was detected in 89% of ICC biopsies with an
average of 3 genotypes per case (range 0-6). High-risk
HPV subtypes were found either as single or multiple
infections in 78% of ICC. Most (~73%) of the ICC cases
harbored the HPV16 genotype either as a single infec-
tion (15%) or along with other HR (30%) or LR (9.1%)
genotypes. In contrast, HPV 16 was rare in women with
lower CIN grades as only 2 of 14 (14%) CIN2-3, 2 of 12
(17%) CIN1, and 3 of 20 (15%) of women with no evi-
dence of cytological abnormalities harbored HPV16
infections. Following HPV16, the next most frequent
genotypes in ICC were HPV35, 45, 18, 31, 52, 33 and 58
(Table 2). These frequencies were all statistically signifi-
cantly higher than in controls. Interestingly, HPV18 was
f o u n di n2 1 %o fI C C ,a n do n l yw h e nH P V 1 6w a sa l s o
present.
Single versus Multiple HPV Infections
Table 3 shows the distribution of single and multiple
HPV infections by lesion grade and cervical cancer
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HPV16 were detected in 60.6% of ICC cases. HR-HPV
genotypes 33, 52, 58, 68 and 82, in multiple infections
with HPV 16, were detected in 30.3% of ICC cases.
When combined, HR-HPV genotypes 16, 18, 31, 33,
35, 45, 52, 58, 68, and 82, they accounted for 90.9% of
all HPV positive ICC cases. HPV16 multiple infections
with LR-HPV genotypes 6, 11, 61, and 81 and other
HPV genotypes (62 and 73), comprised the remaining
9.1% of HPV positive ICC cases. Among all CIN cases,
HPV16 was not the prevalent genotype detected; 93%
of CIN2-3 and all of CIN1 cases had multiple infec-
tions with HPV18, 26, 35, 45, 51, 53, 56, 58, 59, and
66 (Table 3). Whereas of 120 controls or women with
no evidence of cytological or histological abnormalities,
only 20 (14%) were HPV-positive, in which 90% of
multiple infections we detected harbored the same
genotypes (HPV18, 26, 35, 45, 51, 53, 56, 58, 59, and
66 (Table 3).
Discussion
Our key finding was that among women visiting the
KCMC, a tertiary care facility serving 10 million people,
in Northern Tanzania, HPV16, 35 and 45 alone
accounted for most of the invasive cervical cancers
found. These HPV genotypes were rare in CIN lesions
regardless of grade, suggesting that a vaccine that
includes these three genotypes could prevent ~70% of
ICC. Our findings also suggest that ICC risk is higher in
individuals infected with multiple HPV genotypes,
including those considered as high and low risk, sug-
gesting that the cumulative burden of HPV multiple
infections, maybe a marker of differential immune
response. We did not detect any HPV DNA in 11% of
Table 1 Socio-demographic characteristics of study participants
Cancer
(n = 48)
CIN2-3
(n = 17)
CIN1
(n = 21)
CONTROLS
(n = 148)
p-values**
n%n%n%n %
Age 55.2 12.3 44.7 9.8 35.7 12.2 40.3 9.9 <0.0001
Income $ 18 28 39 53 65 80 78 95 <0.0001***
Lifetime sexual partner 0.4* (1,2,3,4)
1 24 52.2 7 43.8 5 25 62 56.5
2 19 41.3 6 37.5 11 55 56 39.2
3 3 6.5 2 12.5 4 20 20 14
4 0 0 1 6.3 0 0 2 1.4
None 2 1 1 5
Marital status 0.6*
Married 30 62.5 10 58.8 15 71.4 107 72.3
Non-married 18 37.5 7 41.2 6 28.5 40 27
HPV <0.0001
Any 33 89.2 14 87.5 12 66.7 20 14.1
None 4 10.8 2 12.5 6 33.3 122 85.9
Genotypes per Case 2.8 3.7 2.7 2.1
Current Smoke 0.6*
Y e s 2 4 . 20000 3 2
No 46 95.8 17 100 21 100 144 98
Oral contraception use 0.003
Yes 19 39.6 10 58.8 16 76.2 98 67.6
No 29 60.4 7 41.2 5 23.8 47 32.4
HIV-1 infection <0.0001*
Yes 6 19.4 9 81.8 9 64.3 23 20.9
No 25 50.6 2 18.2 5 35.7 87 79.1
Tribe 0.3
Chagga 21 43.8 12 70.6 10 47.6 84 57.1
Pare 10 20.8 3 17.7 2 9.5 21 14.3
Others 17 35.4 2 11.8 9 42.9 42 28.6
￿ * p-values is from fisher’s exact chi-squared test due to small cell
￿ ** p-values are exclude missing
￿ *** Poisson regression
￿ Numbers do not necessarily add up to the total due to missing values
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negativity in ICC previously found [11], and similar to
the 11.5% reported elsewhere [8].
While findings of HPV16 association with ICC are
consistent with -current knowledge, our data also sug-
gest that in addition, HPV35 and HPV45 may increase
risk, as observed in a global meta-analysis study [23].
This interpretation is consistent with data found in
other African countries, where HPV16 and HPV18 were
less common than other HR types in CIN1, though
involved in more advanced lesions and cervical cancer
[24-28]. Most of these studies used fresh biopsies for
HPV detection [24,26,27]. We detected HR-HPV16 in
73% of ICC cases, including single and multiple infec-
tions. In the US, HPV16 and 18 combined are found in
cervical cancer at a rate of 70.2% [23], similar to find-
ings in a Canadian study: HPV16 DNA in 52.1% of ICC
and HPV18 DNA in 18.1% of ICC [8]. However, the
Table 2 Distribution of HPV types in CIN1, CIN2, CIN3 and Cervical cancer
HPV test results Cancer
(n = 33)
(%)
CIN2- 3
(n = 14)
(%)
CIN1
(n = 12)
(%)
Controls
(n = 20)
(%)
Single Multiple Single Multiple Single Multiple Single Multiple
High-risk HPV type n=8 n=7 0 n=3 n=2 8 n=4 n=2 2 n=4 n=2 9
Group 1
16 62.5 72.7 33.3 14.2 0 16.6 16.6 15.0
18 0 21.2 33.3 14.2 0 0 16.6 10.0
31 0 18.1 0 14.2 0 0 0 5.0
33 0 9.09 0 14.2 0 0 0 0.0
35 25.0 33.3 0 14.2 25.0 25.0 0 15.0
3 9 00000 8 . 3 00
45 12.5 30.3 0 7.14 0 25.0 16.6 10.0
51 0 0 33.3 14.2 25.0 16.6 0 10.0
52 0 15.1 0 0 0 8.3 0 15.0
56 0 0 0 7.14 0 0 0 5.0
58 0 6.06 0 28.5 50.0 25.0 33.3 25.0
59 0 0 0 7.14 0 25.0 0 5.0
Low-risk HPV type n=0 n=17 n=0 n=8 n=0 n=7 n=3 n=10
Group 2A
68 0 3.03 0 7.14 0 0 0 5.0
Group 2B
26 0 0 0 0 0 0 33.3 5.0
53 0 0 0 35.7 0 25.0 0 5.0
66 0 0 1 14.2 0 0 33.3 15.0
70 0 0 0 0 0 8.3 0 10.0
73 0 15.1 0 21.4 0 8.3 0 15.0
82 0 3.03 0 7.14 0 8.3 33.3 10.0
Group 3
6 0 33.3 0 7.14 0 0 0 0
11 0 9.09 0 0 0 8.3 0 0
Other types n=0 n=6 n=1 n=1 6 n=0 n=4 n=1 n=3
4 0 00000000
42 0 0 0 7.14 0 8.3 100 5.0
55 0 3.03 0 7.14 0 16.6 0 5.0
61 0 0 0 7.14 0 8.3 0 5.0
62 0 3.03 0 21.4 0 16.6 0 0
69 0 0 0 14.2 0 0 0 0
72 0 0 0 7.4 0 8.3 0 5.0
81 0 6.06 0 21.4 0 0 0 10.0
83 0 0 0 28.5 0 16.6 0 0
84 0 0 100 28.5 0 0 0 0
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3.9% and geographic regions of origin are unknown,
while our population was 100% African [8,29]. If these
results can be replicated in a larger study, our findings
would suggest that the association of HPV16 and ICC
in the Tanzanian region may be much higher than that
in other populations. Also, we found five ICC cases with
HPV16 single-genotype infection. However, there were
no ICC cases with single-genotype HPV18 infection.
HPV 35/45/6 and 18/31/73 were the next most fre-
quent genotypes detected in ICC, partly matching
reports by others, where HPV31, 33 and 45 were
among the six most frequently detected genotypes in
ICC in North America [8-10,23]. Our results are simi-
lar to those of the Canadian study, where HPV45 was
one of the three most prominent genotypes in ICC,
ranking ahead of HPV31 and 33 [8]. We could not
identify a clear trend for a specific HPV type that
would suggest lesion progression into cervical cancer.
However, HPV35 and 58 were the only types detected
in CIN1, CIN2-3 and ICC. HR-HPV genotypes 16, 35
and 45 were the major genotypes found in cervical
cancer cases.
Our results show some interesting differences with
global cervical cancer data. The most frequent genotypes
we detected in CIN1 were HPV35, 45 and 53/58/59,
which differ from the most common types detected in
CIN1 in the US, including HPV16, 66, 31, 52 and 51
[10], and HPV 16, 51, 52, 39, 18, 31 in Canada [8]. In
CIN2-3 lesions, we predominantly detected HR-HPV 53
and 58, and the rare genotypes HPV83 and 84. These
findings contrast with those suggesting that the most
prevalent genotypes found in CIN2-3 in the US were
HPV16, 31 and 18, however HPV58 ranked most fre-
quently after 16, 31, and 18 [9,10,23,30]. Disparities
among these studies may be due in part to different
methodologies employed; however the evidence suggests
that geographical differences contribute to HPV type
distribution in cervical intraepithelial neoplasias across
global regions, as reported [23].
The finding that HPV58 was the most prevalent geno-
type, followed by 16, 35, 52, 66, and 73 in equal propor-
tions, are partly consistent with those of a recent meta-
analysis in which the most common HPV genotypes
among women with normal cytology in Eastern Africa
are HPV52, 16, 18, 53 and 66, in order of prevalence
[ 3 1 ] .I nas t u d yi nN o r t h w e s t e r nT a n z a n i a[ 1 7 ]H P V 1 6
and 33 were the main genotypes present in women with
HSIL or advanced CIN; however this study had a small
HSIL sample size (5 of 19 women) and no cancer cases.
The most common genotypes detected among LSIL and
HSIL cases were HPV16, 58, 33 and 18. In Mozambique,
HPV35 was detected as the most prevalent type among
HPV-positive women and among women with HSIL
[14]. A Zimbabwean study found HPV16, 58, 18 and 52
to be the most common genotypes [32] in HIV-1 sero-
positive women with multiple HPV infections. But a
European population-based study could not verify the
oncogenic potential for HPV 58 and 59 in Icelandic
women [7]. In our study, our rankings were not influ-
enced by HIV-1 infection, (data not shown).
Findings that multiple HPV infections were more
common than single infections in CIN1, CIN2-3 and
cancer cases match reports by others [8,33-35]. While it
has been shown that the risk for persistent infection
with one HPV genotype is not synergistically enhanced
by an existing infection with another genotype
[11,36,37], others [38] suggest local levels of HPV-speci-
fic immunoglobulin G (IgG) and IgA in the infected tis-
sue may be insufficient to clear viral infections [38].
Thus, factors that affect humoral immunity, such as
genetic predisposition, frequency of re-infection, genetic
variations of the HPV genotype, and hormone levels
could explain, at least in part, the association between
multiple HPV infections and CIN and ICC in this
region. When adjusting for HIV-1 infections in HPV-
positive women, we found 50% more CIN1 and CIN2-3
lesions in HIV-1 seropositive women with HPV multiple
infections (65%), than in HIV-1 seronegative ones (30%).
While this would support the hypothesis that
Table 3 Distribution of HPV16 and other most prevalent genotypes in CIN lesions and ICC
HPV genotypes ICC
Total (%)
n=3 3
CIN2-3
Total (%)
n=1 4
CIN-1
Total (%)
n=1 2
Controls
Total (%)
n=2 0
HPV-16 only 5 (15.1) 1 (7.1) 0 (0.0) 1 (5.0)
HPV16 with HPV-18 only 5 (15.1) 2 (14.2) 0 (0.0) 2 (10.0)
HPV16 with HPV 18,35,45, or 31 20 (60.6) 2 (14.2) 1 (8.3) 3 (15.0)
HPV16 with HPV 18,31,33,35,45,52,58,68,82 30 (90.9) 2 (14.2) 1 (8.3) 3 (15.0)
HPV16 with HPV 6, 11,18,31,33,35,45,52,58,61,62,68,73,81,82 33 (100) 3 (21.3) 2 (16.6) 4 (20.0)
Other HR-HPV single infections 18,35,45,51,58,66 33 (100) 4 (28.6) 6 (50.0) 8 (40.0)
HPV 18,26,35,45,51,53,56,58,59,66, excluding HPV16 33 (100) 13 (92.8) 12 (100) 18 (90.0)
HPV 18,26,35,42,45,51,53,55,56,58,59,61,66,69,70,72,81,83,84, excluding HPV16 33 (100) 14 (100) 12 (100) 20 (100)
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acquiring multiple infections, 84% of the ICC cases here
reported were HIV-1 negative individuals, (data not
shown).
The main limitation of our study is that these analyses
relied on a small number of cases. However, findings
contribute to HPV knowledge in East Africa that will be
useful for vaccine development and to augment screen-
ing strategies. East Africa continues to have one of the
highest ICC incidence and mortality [39], and cytology-
based screening coverage remains low. Another limita-
tion is that HPV DNA was detected from exfoliated
cells for CIN cases and controls as biopsies were not
medically indicated. Thus, some of the HPVs detected
may not have been related to lesions subsequently
detected. However, cells from homogenized biopsy spe-
cimens were used for HPV detection in the all squa-
mous cell ICC cases. Therefore, limitations
notwithstanding, our ICC findings support the hypoth-
esis that the cumulative burden of multiple HPV geno-
types may contribute to ICC incidence, presumably via
altered immune response.
Conclusions
We found that HPV 16, 35 and 45, but not HPV18,
were the most common HPV subtypes in ICC. HR-HPV
genotypes 45, 53 and 58 significantly contribute to
CIN1, CIN2-3 and ICC rates in Northern Tanzanian
women. Multiple infections were found in the majority
of cancers and high grade CIN. Our data suggest that a
vaccine targeting HPV genotypes 16, 18, 31, 35 and 45,
could help prevent up to 61% of ICC in this region;
while adding HPV genotypes 33, 52, 58, 68, and 82 may
help increase prevention up to 91% of ICC. The low fre-
quency or absence of HPV 16 and 18 in CIN1 or CIN2-
3 may have implications for promoting cytology and
HPV-based screening in this region. Larger studies are
required to confirm these findings.
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